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Abstract
We describe a novel strategy for mRNA normalization in quantitative real-time PCR that is based on expressed Alu
repeat amplification as a measure for the mRNA fraction. We show that expressed Alu repeat amplification is a fast,
accurate normalization tool that can be successfully used for quantification of selected mRNA in the human tran-
scriptome. This result is particularly important for clinical diagnosis and biomarker validation studies based on
mRNA detection in human blood.
Background
Several factors hinder the reliable quantification of
mRNA in gene expression studies performed in human
samples, including sample availability, handling, and sto-
rage and the strategy used to normalize selected mRNA
over the total mRNA fraction. With real-time quantita-
tive RT-PCR (RT-qPCR), quantification errors depend
on variations in the amount of total RNA or cDNA
between samples, which remain difficult to determine.
Various strategies have been applied in efforts to nor-
malize these variations. Under controlled conditions of
reproducible extraction of good-quality RNA, one possi-
ble strategy relies on total RNA quantification (RNA
mass quantity) and/or the use of synthetic internal stan-
dards. To date, the amplification of a reference gene as
the internal standard is the most frequently used
approach to normalizing the mRNA fraction. This strat-
egy is best applied when a large number of target genes
are to be screened and makes inter-laboratory standardi-
zation easier than using total RNA content, which might
depend on the quantification method. However, the reli-
able quantification of selected targets requires identifica-
tion of a proper internal control gene for normalization,
one that exhibits stable expression in the given cell or
tissue under investigation.
A first accurate strategy for normalization was based
on the GeNorm algorithm, which allows identification
of the most stably expressed control genes in a human
tissue of interest. The expression of ten common refer-
ence genes is analyzed in the tissue investigated by RT-
qPCR, and the GeNorm algorithm is applied to calculate
the gene expression stability (M) of the different control
genes. The level of the target gene is normalized over
the normalization factor (NF) obtained from the geo-
metric mean of expression value of three or more stable
reference genes [1].
Although the GeNorm algorithm is a robust normali-
zation method, the reference gene validation requires
extensive experimental work and a high quantity of
sample material. These requirements may represent a
problem in the context of gene expression studies invol-
ving the human transcriptome for which a limited
amount of human tissue samples are available. More-
over, the choice of stable control genes becomes parti-
cularly difficult and is an expensive and lengthy process
in pathological conditions characterized by transcrip-
tional dysregulation. Altered activity of transcription fac-
tors and DNA target sequences may also affect the
stability of mRNA expression levels of the selected refer-
ence gene, thus producing an erroneous quantification
of the selected mRNA. This possibility leads to the
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experimental work before choosing a panel of stable
reference genes.
To avoid these problems, we propose a new strategy
for mRNA normalization in RT-qPCR that is based on
expressed Alu repeat (EAR) amplification as a measure
for the total mRNA fraction. More than one million
copies of the approximately 300-bp Alu element are
interspersed throughout the human genome, with up to
75% of all known genes containing Aluinsertions within
their introns and/or untranslated regions (UTRs) [2].
Therefore, the differential expression of a number of
genes in the tissues or cells under investigation will not
influence EAR abundance in the transcriptome.
In this study, we set up a standardized RT-qPCR pro-
tocol for EAR amplification in the human transcriptome.
We provide evidence that normalization based on EAR
amplification is a suitable, fast, and precise tool for
quantification of selected mRNA by RT-qPCR in human
biological samples.
Results
There is a long-standing interest in brain-derived neuro-
trophic factor (BDNF) because of its implications in
neurodegenerative diseases [3]. BDNF is a neurotrophin
that is crucial for the survival, maintenance, and differ-
entiation of subpopulations of neurons in the central
and peripheral nervous systems. Alterations in BDNF
brain levels and activity have been described in various
neurodegenerative disorders, most notably Huntington’s
disease (HD) [3]. Although BDNF is highly concentrated
in the nervous system, it can also be detected in human
blood and the blood of other mammals [4,5]. Because of
that, several efforts have targeted testing BDNF levels in
blood with the aim of assessing its potential value as a
disease biomarker. For HD and other diseases, such as
depression, schizophrenia, and Alzheimer’sd i s e a s e ,i t s
reliable detection in peripheral tissues may be crucial
for understanding biological and pathogenic processes
in humans and for assessing the potential activity of
candidate therapeutic agents. Unfortunately, in human
blood, this measurement has always proved problematic,
especially for the BDNF protein. In fact, many factors
influence this measurement, including the way the
blood is collected, its storage, and the methodology
employed to prepare the samples [6].
When considering the measurement of blood BDNF
mRNA, recovery and storage of samples are less proble-
matic because the PAXgene™ Blood RNA System (PreA-
nalytiX, QIAGEN, Hilden, Germany) allows stabilization
of intracellular RNA without affecting RNA isolation
and yield. Given the remarkable reduction in brain
BDNF mRNA levels in HD, we set up a fast, accurate,
and standardized method for BDNF mRNA detection in
blood. As for any other mRNA, this approach requires a
normalization procedure that does not affect the experi-
mental data. However, as Figure 1 shows, when the
BDNF mRNA level in blood from eight control partici-
pants was normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA or b2-microglobulin
(b2M) mRNA, the analyses produced different quantifi-
cations of BDNF mRNA levels normalized to these two
different reference genes (median value BDNF mRNA/
GAPDH mRNA, 1; median value BDNF mRNA/b2M
mRNA, 1.6). These data support the notion that RT-
qPCR performed with a conventional normalization
strategy based on a single control gene may lead to
erroneous quantification of target genes in human
blood.
Set up of a new normalization strategy: EAR amplification
In the search for a stable tool for normalization, we
f o c u s e do nE A R sb e c a u s et h e ya r et h em o s ta b u n d a n t
repeats in the human genome. More than 1,500 human
genes contain one or more Alu repeat in the UTRs
regions. The EARs are about 280 nucleotides long and
are divided into 30 well-conserved subfamilies (see [7]
for a review). These features make EAR amplification a
reliable tool for normalization in RT-qPCR based on the
principle that the differential expression of a small num-
ber of genes bearing the EAR will not influence EAR
abundance in the transcriptome. Figure 2a shows a
BLAST representation of EAR element sequence conser-
vation in the human genome. The small blue dots repre-
sent the position of EAR in the intergenic and intragenic
regions and show that EARs are particularly located in
the UTR and intronic regions. The Alu interspersed
repetitive sequence and primers selected for the study
are represented in Figure 2b while Additional file 1
shows the protocol for EAR amplification in the human
transcriptome. As indicated, we first performed a retro-
transcription (RT) reaction with total RNA at a final
concentration of 12.5 ng/μl (see Materials and methods
for additional details). The obtained cDNA was then
diluted 1:200 and 5 μlo ft h i ss o l u t i o nt e s t e du s i n gR T -
qPCR (see Materials and methods). Notably, another
advantage of this assay is in the low amount of cDNA
used for the analyses, allowing many experimental repli-
cates when the starting material (RNA) is limiting. As
Figure 2c shows, we obtained a good RT-qPCR out-
come, as indicated by the PCR efficiency (102%) and
correct slope value (-3.27). In addition, another impor-
tant outcome arises from the analysis of the amplified
products with the melting curve. As Figure 2d shows,
multiple melting peaks emerge from these analyses, and
the expected peaks by amplified products (88,69 T) can
be recognized. This result is anticipated given that sev-
eral peaks are generated by the polymorphisms present
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[7]. We conclude that when working with EARs, differ-
ent melting curves in different samples are to be
expected and that for each sample the replicates have to
share their melting curve.
Comparison of reference gene stability in human blood
versus EARs
As indicated above, the use of NF obtained from the
geometric mean of three or more stable reference genes
is suitable for normalization [1]. We therefore decided
to compare the EAR normalization tool to the normali-
zation performed based on three more stable control
g e n e se x p r e s s e di nb l o o da n ds e l e c t e db yt h eG e N o r m
algorithm. We started by choosing six different refer-
ence genes with expression in human blood that has
been evaluated by RT-qPCR. The GeNorm algorithm
was applied to calculate the M (see Table 1 for full gene
name, accession number, chromosomal localization,
indication that primers span an intron, and primer
sequences). Genes with higher M values have greater
v a r i a t i o ni ne x p r e s s i o n ,a n dt h et h r e s h o l dp r o p o s e df o r
eliminating a gene as unstable was M ≥ 0.5.
On the basis of our analyses, the ranking of the
expression stability in these genes was (from most to
least stable): GNB2L1 (guanine nucleotide binding pro-
tein (G protein), beta polypeptide 2-like 1), HPRT1
(hypoxanthine phosphoribosyltransferase 1), YWHAZ
(tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein, zeta polypeptide), b2M, GAPDH,
and bACT (b-actin) (Figure 3a). As shown, the M values
of GNB2L1, HPRT1,a n dYWHAZ were lower than 0.5;
therefore, these genes were concluded to be stably
expressed reference genes in human blood. The NF
value, used for normalization of RT-qPCR, was calcu-
lated based on the geometric mean of the expression
levels of these three most stable control genes.
To assess the validity of EARs as a normalization tool
versus the GeNorm strategy, we evaluated BDNF
mRNA levels normalized to EARs and to NF in blood
from ten healthy volunteers. Figure 3b shows that the
quantification of BDNF mRNA in human blood is com-
parable after normalization with the two different strate-
gies. The median value shown in Figure 3c confirms
this result: the median values of blood BDNF mRNA
levels normalized versus EARs and versus NF are simi-
lar to each other (0.95 versus 1.1), while the median
value of BDNF mRNA normalized versus GAPDH
mRNA is much lower (0.65). These data indicate that
EARs represent a good tool for normalization and that
Figure 1 BDNF mRNA in human blood normalized to GAPDH and b2M. Median BDNF mRNA levels in the blood of eight control participants
from the Institute of Neurology, MRC Prion Unit, and University College London (UK). The BDNF level was determined by means of quantitative
real-time PCR and normalized to the level of GAPDH mRNA and b2M. The values are the averages of six independent PCR experiments. The
boundary of the box closest to zero indicates the 25th percentile, the line within the box marks the median, and the boundary of the box
farthest from zero indicates the 75th percentile.
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Page 3 of 12Figure 2 EAR amplification protocol in RNA from total blood. (a) BLAST analysis for Alu repeat distribution in the human genome. Alu
repeat sequences are present in the UTRs of many genes. The small blue points indicate the homologous sequences at the Alu human
consensus repeat. (b) Alu human interspersed repetitive sequence and primers used in this study for EAR amplification. (c) Cq of EAR mRNA
plotted against the log of the relative initial amount of the pooled cDNA. (d) Melt-curve diagram generated from the amplification as described
in (c).
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incorrect results.
Subsequently, we applied the EAR normalization tool
for the quantification of BDNF mRNA in the eight con-
trol participants analyzed in Figure 1, in which the mes-
senger level of the neurotrophin is represented relative
to GAPDH or b2M mRNA content. Figure 3d shows the
median value of BDNF mRNA normalized over GAPDH
(1), b2M (1.6), or EARs (0.55). As shown, the distribu-
tion of the BDNF mRNA values normalized to EARs is
tighter with respect to the distribution of BDNF mRNA
normalized to GAPDH or b2M mRNA, indicating that
the EAR normalization strategy removes most of the
non-specific variations arising from the use of an inap-
propriate internal reference gene.
The experiments described above prove the reliability
of the EAR normalization strategy with respect to GeN-
orm as well as the efficiency of this new method with
respect to normalization to as i n g l eh o u s e k e e p i n gg e n e
to measure BDNF mRNA levels in human blood.
EAR normalization applies to the quantification of mRNAs
specifically expressed in blood
To evaluate the reliability of the EAR normalization strat-
egy with other, more blood-specific genes, we analyzed
IL8 (interleukin-8) mRNA levels in blood from control
participants. Validation of EAR normalization for cyto-
kine quantification in blood might be particularly useful
for measuring the balance between pro- and anti-inflam-
matory cytokines in chronic inflammatory disorders or
autoimmune disease. Cytokine mRNA quantification is
therefore of clinical relevance to immuno-monitoring
and for the evaluation of the disease status in patients.
In our measurements of IL8 mRNA levels in ten con-
trol participants, normalized versus EARs and versus
NF, the IL8 mRNA levels with the two different
approaches were similar in single human samples; also,
again, the similar median value obtained (Figure 4b)
confirmed the result.
We concluded that EARs are a suitable normalization
tool for gene expression study of cytokines in human
blood.
EAR normalization for human tissues other than blood
Fast, sensitive, and accurate quantification in RT-qPCR
analysis is a crucial tool not only for assessing mRNA in
human blood but also for evaluating the levels of given
molecules in tissues such as post-mortem human brain.
In a previous study, we analyzed BDNF mRNA levels in
38 post-mortem human cortices from control partici-
pants and HD patients using GAPDH as the reference
gene [8]. The GAPDH gene is, in fact, one of the more
commonly used reference genes in such analyses [9].
Here we tested whether GAPDH i sas t a b l ec o n t r o l
gene for brain tissues versus EAR and whether normali-
zation over EAR still confirms the finding of a robust
Table 1 Primers sequences for GeNorm
Symbol Name NCBI accession
number
Localization Span intro Sequences
ACTB Beta actin NC_001101 Chromosome 7 No Fw:5’-AGTGTGACGTGGACATCCGCA-3’
Rev:5’-GCCAGGGCAGTGATCTCCTTCT-3’
HPRT1 Hypoxanthine purine synthesis
phosphoribosyl-transferase 1
NC_000023.9 Chromosome x Yes Fw:5’-ATGACCAGTCAACAGGGGACAT-3’
Rev: 5’-CAACACTTCGTGGGGTCCTTTTCA-3’
YWHAZ Tyrosine 3-monooxygenase/S
tryptophan 5-monooxygenase activation
protein, zeta polypeptide
NC_000008.9 Chromosome 8 Yes Fw: 5’-CGTTACTTGGCTGAGGTTGCC-3’
Rev: 5’-GTATGCTTGTTGTGACTGATCGAC-3’
GNB2L1 Guanine nucleotide binding protein,
beta polypeptide 2-like 1
NC_000005.8 Chromosome 5 Yes Fw: 5’-GAGTGTGGCCTTCTCCTCTG-3’
Rev: 5’-GCTTGCAGTTAGCCAGGTTCC-3’
B2M Beta-2-microglobulin NC_000015.8 Chromosome 15 No Fw: 5’-GGAGAGAGAATTGAAAAAGTGGAGC-3’
Rev: 5’-GGCTGTGACAAAGTCACATGGTT-3’
GAPDH Glyceraldehyde-3-oxidoreductase
phosphate dehydrogenase
NC_000012.10 Chromosome 12 No Fw: 5’-AGCTGAACGGGAAGCTCACT-3’
Rev: 5’-AGGTCCACCACTGACACGTTG-3’
Marullo et al. Genome Biology 2010, 11:R9
http://genomebiology.com/2010/11/1/R9
Page 5 of 12Figure 3 Validation of EAR as a tool for normalization in RT-qPCR. (a) Application of the GeNorm algorithm to eight genes to identify the
three most stable housekeeping genes in blood. Average expression stability values (M) of remaining control genes during stepwise exclusion of
the least stable control gene in the human blood of eight control participants. (b) Blood BDNF mRNA relative to EAR and to the three most
stably expressed housekeeping genes. Pearson’s correlation r = 0.56; P < 0.05. (c) Median blood BDNF mRNA levels versus GAPDH, versus the
three most stable control genes and versus EAR in ten control participants. Samples used in (a-c) were from the National Neurological Institute-
IRCCS “Carlo Besta”, Milan (Italy). (d) Median blood BDNF mRNA levels versus GAPDH, versus b2M, and versus EAR mRNA in eight control
participants from the Institute of Neurology, MRC Prion Unit, University College London (UK).
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controls [8]. To evaluate the efficiency of GAPDH,w e
used the same RNA as in Zuccato et al. [8] and per-
formed a GeNorm analysis on six different reference
genes. As shown in Figure 5a, the ranking of the expres-
sion stability in these genes was (from most to least
stable): GAPDH, YWHAZ, bACT, b2M, HPRT1,a n d
GNB2L1. The M values of GAPDH were lower than 0.5,
confirming that this gene is a stably expressed reference
gene in human cortex and also validating the previously
performed quantification of the BDNF mRNA in human
HD samples versus controls [8]. Using the same RNA,
we next repeated the analysis of BDNF mRNA levels
and used normalization to EARs or to GAPDH.F i g u r e
5b shows that the BDNF mRNA level was lower in HD
patients with respect to control participants (Mann-
Whitney, P < 0.05, two-tailed test). These data demon-
strate the efficiency of EAR normalization for quantify-
ing a transcript of interest in other human tissues, such
as cerebral cortex, that are normally subjected to a long
post-mortem delay.
Moreover, we extended the application of EAR nor-
malization strategy to samples from skeletal muscle, an
accessible tissue that responds to hormonal, metabolic
and neural inputs. The muscle, therefore, is a reasonable
tissue to examine for gene expression changes that
might be turned into biomarkers for neurodegenerative
diseases [10]. In particular, we have analyzed the expres-
sion levels of TNN1C (troponin C type 1) mRNA, a
stable gene expressed in the skeletal muscle. The GeN-
orm algorithm was applied to evaluate three more stable
control genes expressed in human muscle. On the basis
of our analyses, the ranking of the expression stability in
these genes was (from most to least stable): GNB2L1,
HPRT1, YWHAZ, b2M, GAPDH,a n dbACT (Figure 6a).
As shown, the M values of GNB2L1, HPRT1,a n d
YWHAZ were lower than 0.5; therefore, these genes
w e r ec o n c l u d e dt ob es t a b l ye x p r e s s e dr e f e r e n c eg e n e s
in human skeletal muscle. The NF value, used for nor-
malization of RT-qPCR, was calculated based on the
geometric mean of the expression levels of these three
most stable control genes. Importantly, in our measure-
ments of TNN1C mRNA levels in four control partici-
pants, normalized versus EARs and versus NF, the
TNN1C mRNA levels with the two different approaches
were overlapping in single human samples. Figure 6b
also shows a similar median value between the two
measurements.
The data described above show that, in addition to
peripheral blood, the EAR normalization strategy can be
applied to samples from human brain and skeletal mus-
cle, implying that this method could be used for asses-
sing different human samples.
Discussion
Accurate normalization of mRNA levels is an absolute
prerequisite for obtaining reliable results in gene
expression studies. Recently, considerable attention has
focused on the systematic study of normalization pro-
cedures. Up to the year 2000, a number of articles dis-
cussed the problem of normalizing mRNA values over
a reference gene, indicating that the most commonly
used reference genes, such as GAPDH and bACT,e x h i -
bit variation under different experimental conditions
Figure 4 Application of the EAR normalization tool for the amplification of a specific blood mRNA (IL8). (a) Amplification of blood IL8
mRNA relative to EAR mRNA and to the three most stably expressed housekeeping genes. Pearson’s correlation r = 0.95; P < 0.0001. (b) Median
blood IL8 mRNA levels versus EAR and versus the three most stable control genes in ten control participants. Samples from the National
Neurological Institute-IRCCS “Carlo Besta”, Milan (Italy).
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is not straightforward, and different internal control
genes should be tested in the context of a specific
experimental design. Different groups have faced this
problem [13,14], and interesting strategies have been
proposed. In particular, Vandesompele et al.[ 1 ]e l u c i -
dated the errors related to the common practice of sin-
gle control normalization. The results showed that a
conventional normalization strategy based on a single
reference gene leads to erroneous normalization and
also demonstrated that ideal and universal control
genes do not exist. A proposed alternative strategy is
based on a gene stability measure (M) as the average
pair-wise variation between a particular gene and all
other control genes. This approach has led to the
GeNorm algorithm, which evaluates the M of common
reference genes and allows determination of the most
stably expressed genes in the tissue analyzed during
stepwise exclusion of the worst scoring gene points
[1]. The rationale for this analysis is that a normaliza-
tion factor based on proper internal control genes
should remove all non-specific variation. This robust
procedure has led to more accurate gene expression
studies; however, the method must be set up for differ-
ent tissues analyzed and requires a high number of
replicates, involving extensive experimental work and
twice the amount of sample material. Despite being an
important development, the GeNorm strategy does not
completely satisfy the need for a universal method for
normalization in RT-qPCR.
Figure 5 BDNF mRNA level normalized to EAR in the human post-mortem cortex (a) Application of the GeNorm algorithm to six
genes to identify the three most stable housekeeping genes in human post-mortem cortex. Average expression stability values (M) of
remaining control genes during stepwise exclusion of the least stable control gene in the human cortex of seven control participants. (b) BDNF
mRNA levels in the human cortex of seven control participants and seven HD patients normalized to GAPDH (Zuccato et al. [8]) and EAR mRNA.
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EARs in UTRs of 1,500 genes makes the development of
this novel strategy an important tool for normalization.
In fact, even the transcriptional dysregulation that char-
acterizes several pathological conditions does not signifi-
cantly alter the total amount of EARs in the whole
human transcriptome. This scenario applies in HD, in
which the activity of several transcription factors and
related DNA target sequences is impaired [15], thus spe-
cifically complicating the choice of a suitably stable
reference gene both in the control and HD population.
One of the selected mRNA targets in this study,
BDNF, is reported to be involved in the pathogenesis of
HD [3,16]. Previous studies have shown that BDNF
mRNA is consistently reduced in cells and in vivo brain
tissues from HD transgenic mice and patients [3]. In
addition, blood BDNF levels correlate with brain BDNF
levels and disease progression in HD mice [17]. The
protocol described here for the rapid and accurate eva-
luation of BDNF mRNA in human blood samples repre-
sents a step forward in efforts to develop a reliable
measurement of key mRNA in blood. Moreover, we
Figure 6 Normalization to EAR and GeNorm to evaluate TNNC1 mRNA levels, a gene specifically expressed in human skeletal muscle.
(a) Application of the GeNorm algorithm to six genes to identify the three most stable housekeeping genes in human skeletal muscle. Average
expression stability values (M) of remaining control genes during stepwise exclusion of the least stable control gene in the human skeletal
muscle of four control participants. (b) Median skeletal muscle TNNC1 mRNA levels versus EAR and versus the three most stable control genes in
four control participants. Samples from the National Neurological Institute-IRCCS “Carlo Besta”, Milan (Italy). Pearson’s correlation r = 0.94; P < 0.05
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EARs are comparable to those obtained after normaliza-
tion using the most robust normalization strategies
available in both analyzed tissues.
More important, given the widespread distribution of
EARs in the human genome and the absence of any tis-
sue specificity in their expression, the EAR normaliza-
tion tool described here can be universally applied to
human biological samples (blood, skeletal muscle and
post-mortem brain tissues), avoiding the time-consum-
ing and expensive experimental work needed for selec-
tion and analysis of the most stable reference genes in
the chosen tissue. It should be noted that the EAR nor-
malization strategy minimizes the amount of RNA used
for the analysis, an important advantage for expression
studies on samples characterized by a limited amount of
RNA where it would otherwise be very difficult to use
alternative methods such as GeNorm.
Conclusions
A reliable and flexible normalization strategy has been an
urgent need in the context of gene expression studies in
human samples. We have identified a suitable novel nor-
malization strategy that can be applied in different types
of human biological material. EAR normalization enables
the validation of an appropriate control gene for any spe-
cific experimental design to be avoided. More important,
the strategy of reducing non-specific variation in samples
by normalizing to EAR enables a straightforward assess-
ment of relevant biological variation from mRNA levels.
This possibility is particularly important in the context of
clinical studies for evaluating the alteration of mRNA
levels as reliable markers of disease progression.
Materials and methods
Recruitment of healthy volunteers
Individuals were recruited for the study from the
National Hospital for Neurology and Neurosurgery,
London (UK) and the National Neurological Institute-
IRCCS “Carlo Besta”, Milan (Italy). Full ethical review
and consent was obtained for the research use of blood
and skeletal muscle from healthy volunteers and all sub-
jects gave informed written consent. Table 2 gives parti-
cipant demographic characteristics.
Human tissue collection
Blood collection
A total of 2.5 ml whole venous blood was collected in
an evacuated blood collection tube (PAXgene™ Blood
RNA Tube, BD Vacutainer™, Plymouth, UK) containing
a stabilizing additive. After sample collection, the PAX
tubes were incubated and stabilized at room tempera-
ture for 2 hours, followed by immediate storage at -20°C
until RNA extraction.
Skeletal muscle collection
Biopsies of vastus lateralis muscle were obtained after
informed consent from National Neurological Institute-
IRCCS “Carlo Besta” (Italy). Biopsies were obtained
under local anesthesia and immediately frozen in dry ice
or liquid nitrogen.
RNA extraction
RNA was extracted from whole blood using the PAX-
gene™ Blood RNA System Kit (PreAnalytiX, QIAGEN)
following the manufacturer’sg u i d e l i n e s .T o t a lR N A
concentration and purity were measured using a Nano-
Drop 1000 Spectrophotometer (Thermo Scientific, Wal-
tham, MA, USA), and quality was verified by means of
agarose gel electrophoresis of 1 μgo fe a c hs a m p l e
(Additional data file 2). The total RNA was stored in
aliquots at -80°C.
The muscle samples were homogenized in TRIZOL
(Invitrogen, Carlsbad, CA, USA) using a Ultraturex
homogeniser. Total RNA was isolated according to the
manufacturer’s protocol and stored in aliquots at -80°C.
RNA retrotranscription
Using Superscript III RNaseH reverse transcriptase
(Invitrogen) and random primers in a volume of 20 μl,
250 ng total RNA was reverse-transcribed to single-
stranded cDNA, according to the manufacturer’s
instructions.
Real-time PCR
Three independent PCR analyses were performed of
each of two independent RT reactions, for a total of six
independent measurements for each of the analyzed
mRNA samples.
BDNF, IL8, TNNC1 and housekeeping genes
Using an iCycler Thermal Cycler with a Multicolor
Real-time PCR Detection System (Bio-Rad, Hercules,
CA, USA), all of the reactions were performed in a total
volume of 25 μl containing 5 μl of cDNA from a 1:10
RT dilution, 50 mM KCl, 20 mM Tris-HCI, pH 8.4, 0.2
mM dNTPs, iTaq DNA polymerase, 25 units/ml, 3 mM
Table 2 Characteristics of the study
Number Gender
(F/M)
Age
(years)
Blood
University College London (UK) 8 4/4 44 (28-62)
Institute-IRCCS “Carlo Besta”
(Italy)
10 7/3 31 (23-45)
Skeletal muscle
Institute-IRCCS “Carlo Besta”
(Italy)
4 2/2 35 (24-46)
F: female; M: male
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(iQTM SYBR Green Supermix, Bio-Rad), and 0.3 μMo f
forward and reverse primers. The amplification cycles
consisted of an initial denaturing cycle at 95°C for 3
minutes, followed by 45 cycles of 30 s at 95°C, 30 s at
60°C, and 30 s at 72°C. Fluorescence was quantified dur-
ing the 60°C annealing step, and product formation was
confirmed by means of a melting curve analysis (55 to
94°C). The amounts of BDNF and IL8 mRNA were nor-
malized to the geometric mean of the three most stable
housekeeping genes (HPRT1, YWHAZ,a n dGNB2L;
Table 1 for primer sequences).
The BDNF-specific primers set up on the BDNF cod-
ing sequence (GenBank accession number AF411339)
were BDNF 5’-TAACGGCGGCAGACAAAAAGA-3’
and BDNF 5’-GAAGTATTGCTTCAGTTGGCCT-3’.
The obtained amplification product was 101 bp long.
The IL8-specific primers were set up referring to Gen-
Bank accession number NM_000584.2; the primer
sequences were IL8 5’-CCATCTCACTGTGTGTAAA-
CATGAC-3’ and IL8 5’-TCCACTCTCAATCACTCT-
CAGTTCT-3’. The obtained amplification product was
194 bp long. The TNNC1-specific primers were set up
referring to GenBank accession number NM_003280.2;
the primer sequences were TNNC1 5’-TGCAGGAGAT-
GATCGATGAGGTG-3’ and TNNC1 5’-TGCGGAA-
GAGGTCAGACAGCTC-3’. The obtained amplification
product was 138 bp long.
EARs
Using an iCycler Thermal Cycler with a Multicolor
Real-time PCR Detection System (Bio-Rad), all of the
reactions were performed in a total volume of 25 μl
containing 5 μlo fc D N Af r o ma1 : 2 0 0R Td i l u t i o n ,5 0
mM KCl, 20 mM Tris-HCI, pH 8.4, 0.2 mM dNTPs,
iTaq DNA polymerase, 25 units/ml, 3 mM MgCl2,
SYBR Green I, 10 nM fluorescein, stabilizers (iQTM
SYBR Green Supermix, Bio-Rad), and 0.3 μM of forward
and reverse primers. The amplification cycles consisted
of an initial denaturing cycle at 95°C for 3 minutes, fol-
lowed by 45 cycles of 30 s at 95°C, 30 s at 60°C, and 30
s at 72°C. Fluorescence was quantified during the 60°C
annealing step, and product formation was confirmed by
means of a melting curve analysis (55 to 94°C).
T h eE A R - s p e c i f i cp r i m e r sw e r es e tu po na nA l u
human interspersed repetitive sequence (Figure 2b). The
primer sequences were EAR 5’-GAGGCTGAGGCAG-
GAGAATCG-3’ and EAR 5’-GTCGCCCAGGCTG-
GAGTG-3’. The obtained amplification product was 87
bp long.
Statistical analyses and data representation
Because BDNF values did not have a normal distribution,
the non-parametric Mann-Whitney two-tailed U-test was
used for the statistical analyses, with significance set at
P < 0.05. Median values were chosen because of the
skewed distribution of the data. In each figure, the
boundary of the box closest to zero indicates the 25th
percentile, the line within the box marks the median or
50th percentile, and the boundary of the box farthest
from zero indicates the 75th percentile. When ten or
more samples were analyzed, whiskers above and below
the box indicate the 90th and 10th percentiles.
The validation of the EAR normalization strategy with
respect to the GeNorm algorithm was measured using
Pearson correlations (r).
The materials and methods section and nomenclature
follows the MIQE reporting guidelines [18].
Additional file 1: Protocol for EAR amplification in the human
transcriptome Protocol for EAR amplification in the human
transcriptome.
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-1-r9-
S1.pdf]
Additional file 2: A selection of RNA from peripheral blood used in
this study A selection of RNA from peripheral blood used in this study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/gb-2010-11-1-r9-
S2.pdf]
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